相关实验视频

Updated: Jan 16, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

在局部晚期子宫癌中Endostar加化学放射治疗的有效性:一个多中心的II期随机试验

Fang Wu¹, Xiaobi Tang², Wenqi Liu³

¹Department of Radiation Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.

Therapeutic advances in medical oncology

|October 6, 2025

概括

将Endostar添加到并发化学辐射疗法 (CCRT) 显著改善了全方位响应率,并减少了局部区域高级宫癌 (LACC) 患者的远程转移. 这种组合疗法在不增加毒性的情况下显示出有希望的结果,为LACC提供了潜在的新治疗选择.

科学领域:

在瘤学瘤学.
辐射疗法辐射疗法
医学瘤学医学瘤学

背景情况:

宫癌是妇女死亡的主要原因,70%的病例被诊断为局部晚期 (LACC).
同时化学放射治疗 (CCRT) 是LACC的标准,但超过30%的患者出现复发或转移.
改善LACC的治疗结果是一个关键的全球卫生目标.

研究的目的:

评估将Endostar纳入LACC患者的CCRT中的安全性和有效性.
为了确定Endostar是否与单独使用CCRT相比,改善了治疗反应和生存结果.

主要方法:

一个多中心的,随机的,受控的II期试验,涉及120名LACC患者.
患者被分配给单独的CCRT或CCRT加Endostar.
恩多斯塔尔每15天服用7.5mg/m2/天10天,每15天一次,从CCRT前5天开始.

主要成果:

CCRT加Endostar组显示出显著更高的完全响应率 (68.3%对35.0%,p=0.001).
远程无转移存活 (DMFS) 显著改善了CCRT加Endostar (5年:88.0%对比67.0%,p=0.029).
没有观察到总体存活率,无进展存活率或局部无复发存活率的显著差异;不同组的不良事件相似.

结论:

将Endostar添加到CCRT显著增强瘤反应,并减少LACC患者的远程转移,而不会增加毒性.
患有状细胞癌,瘤直径大于4厘米或IB2/IIA2-IIB阶段疾病的患者特别受益于组合治疗方案.
需要在III期试验中进一步验证,以确定这种组合作为LACC的新标准治疗方法.

关键词:

恒星中的恒星 (Endostar) 是一个恒星.血管新生抑制剂血管新生抑制剂宫癌:子宫癌是一种癌症.化学疗法或放射治疗有效性有效性有效性.在安全方面,安全是安全的.

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...